Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.56M P/E - EPS this Y - Ern Qtrly Grth -
Income -13.27M Forward P/E - EPS next Y - 50D Avg Chg 14.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -78.00%
Recommedations - Quick Ratio 0.69 Shares Outstanding 33.24M 52W Low Chg 68.00%
Insider Own 25.72% ROA -173.43% Shares Float 13.64M Beta -3.03
Inst Own 2.49% ROE -2,968.51% Shares Shorted/Prior 92.48K/50.79K Price 1.55
Gross Margin - Profit Margin - Avg. Volume 176,445 Target Price -
Oper. Margin - Earnings Date - Volume 43,516 Change -4.32%
About OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited News
05/08/24 OKYO Pharma Announces Participation in May 2024 Investor Conferences
04/30/24 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
04/08/24 OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
04/02/24 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
03/22/24 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
03/21/24 OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
03/20/24 OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
07:00 AM OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
01/31/24 OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
01/08/24 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
01/05/24 OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
12/04/23 OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
10/31/23 OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
06:00 AM OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (β€œNCP”)
10/05/23 OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
09/15/23 OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
09/14/23 OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
09/14/23 OKYO Pharma Limited Announces Withdrawal of Public Offering
09/13/23 OKYO Pharma Announces Public Offering of Ordinary Shares
09/08/23 OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
OKYO Chatroom

User Image Rounderssss4 Posted - 1 day ago

$OKYO We need a PR Gary ,give us something positive to talk about

User Image Stock_Titan Posted - 1 day ago

$OKYO OKYO Pharma Announces Participation in May 2024 Investor Conferences https://www.stocktitan.net/news/OKYO/okyo-pharma-announces-participation-in-may-2024-investor-zwr870hqvx66.html

User Image Rounderssss4 Posted - 1 week ago

$OKYO Drop some big news here Gary

User Image Rounderssss4 Posted - 04/30/24

$NLSP need this, $CADL which I did mention that in discord, and $OKYO on Friday for the trifecta wins this week.

User Image Stock_Titan Posted - 04/30/24

$OKYO OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) https://www.stocktitan.net/news/OKYO/okyo-pharma-announces-upcoming-presentation-of-ok-101-phase-2-data-jnmjrkztsbnz.html

User Image rp6577 Posted - 04/30/24

$OKYO been quiet here. I have a feeling something is going on in the background. Could get a surprise positive PR soon

User Image Jabed206 Posted - 04/28/24

$OKYO Gary Jacob company πŸ˜†

User Image rp6577 Posted - 04/26/24

$OKYO starting to perk up

User Image Rounderssss4 Posted - 04/26/24

$OKYO πŸ‘€ @jacksparo @Paraboljoker moving looking for breakout πŸš€, Keep it on your radar

User Image Rounderssss4 Posted - 04/17/24

@jacksparo @Paraboljoker πŸ‘€eyes on it $OKYO

User Image Bombar79 Posted - 04/17/24

$VNDA ok, we have an offer of 7.75, a ceo saying 7.75 is way under value of the company. In normal condtions stock price should be at 7.75 an is at 5.5🀬🀬🀬 $WISA $INVO $OKYO

User Image Rounderssss4 Posted - 04/17/24

$VNDA sliding some profits into $NLSP for the partnership and a big chunk into $OKYO πŸš€ need also $CADL to announce positive results in nsclc trial very soon, let's make some money today it's a tough market. Secure profits when you can

User Image Rounderssss4 Posted - 04/16/24

@jacksparo @Paraboljoker *sorry $OKYO was the stock πŸ˜‚

User Image Rounderssss4 Posted - 04/16/24

@mailman1961 $OKYO , ready for it to break out of this range

User Image Rounderssss4 Posted - 04/15/24

$OKYO give us some news

User Image Stock_Titan Posted - 1 month ago

$OKYO OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 https://www.stocktitan.net/news/OKYO/okyo-pharma-to-reschedule-key-opinion-leader-event-in-dry-eye-los57npi7e1k.html

User Image Rounderssss4 Posted - 1 month ago

$OKYO The company will be hosting a Key Opinion Leader event featuring Jay Pepose, MD, PhD, and Anat Galor, MD, MSPH, who will discuss these significant findings in depth. Event Details: April 9th, 2024, 12:00 PM ET

User Image matfabrix Posted - 1 month ago

$OKYO presentation didn’t happen?

User Image Rounderssss4 Posted - 1 month ago

$OKYO presentation in 45 minutes and 8k shares traded today πŸ€”

User Image rp6577 Posted - 1 month ago

$OKYO looking solid

User Image Rounderssss4 Posted - 1 month ago

$OKYO run to 2 would be nice , should get some attention between today and tomorrow

User Image indyscot Posted - 1 month ago

$DXYZ $FFIE $RDDT $TSLA $OKYO

User Image Stock_Titan Posted - 1 month ago

$OKYO OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery https://www.stocktitan.net/news/OKYO/okyo-pharma-announces-upcoming-presentation-of-ok-101-phase-2-data-kl3wf03yi8ny.html

User Image Procdeez Posted - 03/26/24

$OKYO

User Image TimingTimingTiming Posted - 03/25/24

$OKYO What pussies are selling this are you fucking serious do you have any fucking clue how big the dry-eye market is this is a diamond in the rough buy the fuck out of it

User Image TimingTimingTiming Posted - 03/25/24

$OKYO Long

User Image Trainop Posted - 03/25/24

$OKYO Shorts will lose their shirts if we BUY, BUY BUY $7 in view sooner than later if we GO GO GO

User Image rp6577 Posted - 03/23/24

$OKYO phase 3 won’t take very long. In a relatively short order, this company could get FDA approval and will likely be sold around the 1bn level. Just sit back and add on dips $XBI

User Image Stocksrunner Posted - 03/22/24

Friday Flops πŸ˜” But Don't Fret, There's Always Next Week! $NKTX πŸ“‰ shares took a tumble, but their novel autoimmune treatments show promise! $ISPR πŸ’¨ offering diluted investors, yet innovation lies ahead! $LULU πŸ‘Ÿ guidance sparked a selloff, but their athleisure empire won't crumble. $DJT πŸ‘” Trump's social media merger saw DWAC sink, but his loyal fans may revive it. $OKYO πŸ‘€ While OKYO Pharma's dry eye candidate shined, the market blinked. Every down day plants the seeds for future rebounds! Stay resilient, traders! πŸ’ͺ

User Image success2max Posted - 03/22/24

$OKYO come on baby lets run. please ha

Analyst Ratings
HC Wainwright & Co. Buy Mar 22, 24
HC Wainwright & Co. Buy Jan 8, 24
HC Wainwright & Co. Buy Dec 5, 23
HC Wainwright & Co. Buy Nov 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BRANCACCIO JOHN P Director Director Sep 15 Buy 1.50 16,670 25,005 16,670 09/28/23
CERRONE GABRIELE M Executive Chairman Executive Chairman May 19 Buy 0.076 5,800,000 440,800 548,981,215 05/20/22